• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Alpine Immune Sciences, Inc.

    < Previous 1 2 Next >
    Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Proposed Public Offering
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Participation in May Investor Conferences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Participation in January Investor Conferences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.